CRISPR Therapeutics AG (STU:1CG) EV-to-EBIT : -9.54 (As of May. 15, 2024)

View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CRISPR Therapeutics AG's Enterprise Value is €2,647.6 Mil. CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-277.5 Mil. Therefore, CRISPR Therapeutics AG's EV-to-EBIT for today is -9.54.

The historical rank and industry rank for CRISPR Therapeutics AG's EV-to-EBIT or its related term are showing as below:

STU:1CG' s EV-to-EBIT Range Over the Past 10 Years
Min: -1157.03 Med: -9.78 Max: 169.94
Current: -9.55

During the past 10 years, the highest EV-to-EBIT of CRISPR Therapeutics AG was 169.94. The lowest was -1157.03. And the median was -9.78.

STU:1CG's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs STU:1CG: -9.55

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CRISPR Therapeutics AG's Enterprise Value for the quarter that ended in Mar. 2024 was €1,738.0 Mil. CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-277.5 Mil. CRISPR Therapeutics AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -15.97%.

CRISPR Therapeutics AG EV-to-EBIT Historical Data

The historical data trend for CRISPR Therapeutics AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG EV-to-EBIT Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

60.14

-27.33

9.85

-2.41

-15.98

CRISPR Therapeutics AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-3.43	-6.19	-4.97	-15.98	-13.09

Competitive Comparison of CRISPR Therapeutics AG's EV-to-EBIT

For the Biotechnology subindustry, CRISPR Therapeutics AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's EV-to-EBIT falls into.

CRISPR Therapeutics AG EV-to-EBIT Calculation

CRISPR Therapeutics AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2647.630	/	-277.492
	=	-9.54

CRISPR Therapeutics AG's current Enterprise Value is €2,647.6 Mil.
CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-277.5 Mil.

CRISPR Therapeutics AG (STU:1CG) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CRISPR Therapeutics AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-277.492	/	1738.03208
	=	-15.97 %

CRISPR Therapeutics AG's Enterprise Value for the quarter that ended in Mar. 2024 was €1,738.0 Mil.
CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-277.5 Mil.

CRISPR Therapeutics AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG (STU:1CG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (STU:1CG) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CRSP:USA CRSP:Mexico

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (STU:1CG) Headlines

No Headlines